Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating oxygen therapy strategies in patients with chronic obstructive pulmonary disease COPD admitted to the intensive care unit ICU due to acute exacerbations. The study compares controlled oxygen therapy aiming for an oxygen saturation of 88-92% to standard oxygen therapy targeting saturation above 94%. This trial aims to determine if controlled oxygen therapy reduces the duration of mechanical ventilation and improves other clinical outcomes in critically ill patients. Participants are assigned to one of two groups the controlled oxygen therapy group receives oxygen through adjustable devices such as nasal cannulas, Venturi masks, or heated high-flow humidified systems to maintain oxygen saturation between 88% and 92%. The standard oxygen therapy group receives oxygen as per usual ICU practice targeting saturation above 94%. The study follows participants for up to 28 days after randomization. During the trial, researchers monitor the total time participants require mechanical ventilation, including invasive and non-invasive methods. Secondary assessments include mortality at 28 days, length of ICU stay, the need for invasive ventilation, and any adverse effects related to high oxygen levels. Participants are closely observed throughout their ICU stay, with data collected to evaluate the outcomes of the two oxygen therapy strategies.
Actively Recruiting
Axial myopia is a form of nearsightedness caused by the eye being too long from front to back, leading to blurry distant vision. It typically begins in childhood and worsens as the eyes grow longer, potentially causing serious eye issues later in life. Researchers are studying T10430 eye drops to see if they can slow or stop this progression in children aged 6 to 11 years, aiming to prevent more severe complications. This Phase 2 trial also evaluates the safety of T10430 based on encouraging animal study results. Participants will be randomly assigned to receive one of three different strengths of T10430 eye drops or a placebo. Each participant will instill one drop in each eye once daily at around 8 PM for up to 56 weeks, followed by a 4-week follow-up period. The study will include about 200 children with axial myopia, and the treatments will be given under double-blind conditions so neither participants nor researchers know which dose is administered. Throughout the study, children and their guardians will attend visits for physical and eye examinations to monitor safety and treatment effects. Researchers will measure treatment-emergent adverse events during the entire study period of up to 60 weeks. They will also assess changes in axial eye length and spherical equivalent refraction at 6 and 12 months. This careful monitoring aims to understand how T10430 impacts eye growth and vision while ensuring participant safety.